. [eighty two] to evaluate the efficacy, basic safety and tolerability of Cannabidiol as an adjunct therapy in conjunction with anti-epileptic medicines over the people struggling from tuberous sclerosis advanced whose most frequent neurological symptom is epilepsy. In this particular medical de